Ju Fu Tang Biotech Holdings Co., Ltd.

As of September 30, 2023, Ju Fu Tang Biotech Holdings Co., Ltd. carries a market capitalization of 42.26M, placing it among publicly traded companies globally. Its enterprise value stands at 29.08M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of September 30, 2023, Ju Fu Tang Biotech Holdings Co., Ltd. has 301.86M shares outstanding.

These figures are as of September 30, 2023. The price-to-sales ratio is 0.48, and the price-to-book ratio stands at 1.37.

These figures are as of September 30, 2023. The EV/Sales ratio of 0.33 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 29.08M versus a market cap of 42.26M, with the gap driven by net debt and cash on the balance sheet.

As of September 30, 2023, Ju Fu Tang Biotech Holdings Co., Ltd. maintains a current ratio of 1.49, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 38.81, indicating elevated leverage, while an interest coverage ratio of -80.19 demonstrates limited ability to service its debt obligations.

Over the twelve months ended September 30, 2023, Ju Fu Tang Biotech Holdings Co., Ltd. posted a negative return on equity (ROE) of -64.19, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -26.96, reflecting losses generated across the asset base. The company generates approximately 2.46M in revenue per employee across its workforce of 35.50, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Ju Fu Tang Biotech Holdings Co., Ltd.'s stock has declined approximately 66.15% over the past 52 weeks. The 50-day moving average sits at 0.10, while the 200-day moving average is 0.22.

Over the twelve months ended September 30, 2023, Ju Fu Tang Biotech Holdings Co., Ltd. generated 87.35M in revenue and converted that into -29.23M in net income, yielding earnings per share of -0.10. EBITDA reached -28.87M, while operating income came in at -18,000.00.

As of September 30, 2023, Ju Fu Tang Biotech Holdings Co., Ltd. holds 25.19M in cash and equivalents against 12.00M in total debt, resulting in a net debt position of 10.03M. Total book value stands at 30.92M, with working capital of 30.64M providing operational flexibility.

Over the twelve months ended September 30, 2023, Ju Fu Tang Biotech Holdings Co., Ltd. posted a gross margin of 2.12, reflecting its pricing power and cost economics. The operating margin of -0.02 and net profit margin of -33.46 provide insight into operational efficiency.

Ju Fu Tang Biotech Holdings Co., Ltd.'s most recent stock split took place on September 14, 2021 with a 7:8 split ratio.

As of September 30, 2023, Ju Fu Tang Biotech Holdings Co., Ltd. has an Altman Z-Score of 0.26, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.